Joseph Pitts said...
I was concerned that CMS finalized its Part B payment policy for biosimilars last year combining all biosimilars into one average sales price calculation and payment code.
Context
Pitts expresses concern over CMS's payment policy for biosimilars potentially harming market entry.
02/03/2016